From Bank of England Governor to Canada’s Prime Minister: Why Mark Carney’s Clash With America Could Benefit the NHS

Why this moment matters

Canada’s rupture with Washington is important because the argument is no longer only about the tariff on a car or a tonne of steel. In the negotiations described in the source article, the dispute widened into questions of sovereignty, industrial policy and whether Canada should align parts of its future trade policy with the United States. Mark Carney ultimately chose to walk away rather than accept terms his government considered too constraining. That decision points to something larger: countries that have spent decades organising trade around the United States are beginning to ask what a more diversified network of alliances should look like.

Healthcare should be near the top of that discussion. Medicines, medical devices, research, cloud infrastructure, AI, data, specialist staff and advanced manufacturing all move across borders. A new network of partnerships between Britain, the European Union, Canada and other like-minded markets would not replace the United States, but it could reduce dependence on a single centre of gravity and create much greater negotiating power for public health systems.

Europe still has scale, and scale matters

Europe is not a secondary market. EFPIA’s 2025 industry figures put Europe at 22.7% of the global prescription pharmaceutical market in 2024, second only to North America at 54.8%. The World Bank estimates the European Union’s 2025 GDP at about $21.24 trillion. Add the United Kingdom’s roughly $4.00 trillion economy and the combined economic base is more than $25 trillion. That is the scale of a market that can shape pricing, regulation, evidence requirements and investment decisions if it acts coherently.

That is why the opportunity created by the current trade realignment is potentially significant. If Canada looks more deliberately towards Europe, and Britain uses its position between the EU, North America, the Gulf and Asia more intelligently, health can become one of the sectors in which new partnerships are built fastest. The NHS has unusual assets to bring to that table: a universal health system, large patient populations, longitudinal data, national research networks, genomic capability, globally recognised universities and substantial medicines purchasing power.

What it could mean for patients

For patients, the most important opportunity is faster access to innovation. Drug development increasingly depends on locating precise patient populations quickly, especially in oncology, rare disease, haematology, genomics and advanced therapies. If Britain, Canada and European countries create more compatible routes for evidence generation, real-world data and trial delivery, companies could treat the region as a larger research ecosystem rather than a series of small disconnected markets.

That matters because Europe has been losing ground. EFPIA and Frontier Economics report that Europe’s share of global industry clinical trials fell from 22% in 2013 to 12% in 2023 even as global trial activity increased by 38%. The result is not abstract: EFPIA estimates the shift equates to around 60,000 fewer clinical-trial places for European patients. A period of geopolitical realignment could be used to reverse that trajectory by making cross-border studies easier, faster and commercially attractive.

Staff, science and technology

Health systems are people businesses as much as technology businesses. Britain, Canada and most of Europe face shortages in parts of the clinical workforce while simultaneously competing for researchers, data scientists, engineers and specialist manufacturing skills. Deeper partnerships could support easier recognition of qualifications, joint fellowships, shared research posts and more structured movement of scarce expertise between systems.

Technology is equally important. Europe remains heavily dependent on American cloud infrastructure, software platforms and AI suppliers. The answer is not to shut those companies out. It is to create credible alternatives and ensure that health systems retain choice. Canada, Britain and Europe could collaborate on sovereign health-data infrastructure, cyber security, medical AI, interoperability and research platforms. More competition would strengthen resilience and improve procurement leverage.

Market access, pricing and the cost of medicines

The trade realignment could cut both ways. Fragmentation can raise costs if manufacturers face duplicated regulatory processes, parallel evidence requirements, tariffs or more complex supply chains. Large pharmaceutical companies may also prioritise markets that are faster and more predictable. Europe cannot assume that its scale alone guarantees early launches.

But that is precisely why collaboration matters. Coordinated health technology assessment, joint horizon scanning, shared evidence frameworks and smarter contracting can lower duplication while improving bargaining power. The NHS is already a major purchaser: NHS Business Services Authority estimates that commissioners in England spent £20.9 billion in 2024/25 on medicines, appliances and medical devices after central rebates. That purchasing power should be treated as a strategic asset, not simply a budget line.

Britain could offer manufacturers something more valuable than a price negotiation alone: a route into a national market, access to high-quality research infrastructure, real-world evidence, genomics, trial recruitment and potentially wider partnerships with European and Canadian health systems. In return, the NHS could seek better launch commitments, more resilient supply, fairer pricing, research investment and manufacturing commitments where appropriate.

What the NHS should do next

1. Make market access an international strategy, not a domestic process.

The NHS and UK life-sciences system should actively shape new UK-Canada-European routes for trials, evidence, digital health and access rather than waiting for commercial patterns to emerge.

2. Build a faster research proposition.

The UK should make national patient identification, contracting, site activation and real-world evidence a coherent offer to global life-sciences companies.

3. Use purchasing power intelligently.

The goal should not simply be the lowest possible medicine price. The NHS should negotiate for the best combination of price, supply security, launch timing, evidence generation and investment.

4. Treat health data and AI as strategic infrastructure.

Britain should remain open to the best global technology while developing sovereign capability, interoperable standards and credible alternatives to single-vendor dependency.

5. Build workforce partnerships into trade relationships.

Health agreements should include researchers, specialist clinicians, training, mutual recognition and joint programmes where this improves capacity and patient care.

Public data and source notes

1. The New York Times, 25–26 August 2026: account of the collapse of U.S.-Canada trade talks supplied by the author/editorial team.

2. EFPIA, The Pharmaceutical Industry in Figures 2025: 2024 prescription-market shares; North America 54.8%, Europe 22.7%, Africa/Asia/Australia 7.4%, China 7.1%, Latin America 4.1%, Japan 4.0%.

3. EFPIA / Frontier Economics, 2026: Europe’s share of global industry clinical trials fell from 22% in 2013 to 12% in 2023 while global trial activity increased 38%; approximately 60,000 fewer trial places for Europeans.

4. World Bank, World Development Indicators, 2025 GDP current US$: United States $30.77tn; European Union $21.24tn; China $19.50tn; United Kingdom $4.00tn.

5. NHS England, Consultant-led Referral to Treatment Waiting Times, June 2026: 7.27 million incomplete pathways; supporting published summaries report 65.8% within 18 weeks and 105,711 pathways over 52 weeks.

6. NHS Business Services Authority, Prescribing Costs in Hospitals and the Community, England 2024/25: estimated £20.9bn commissioner spend after £660m in central rebates.

7. Department of Health and Social Care, UK Clinical Research Delivery KPIs, 2026: official indicators covering study set-up, delivery, recruitment and portfolio activity.